Effect of combined treatment with cyclophosphamidum and allicin on neuroblastoma–bearing mice  by Gao, Xiang-Yang et al.
137
Contents lists available at ScienceDirect
ELSEVIER
Document heading
Asian Pacific journal of Tropical Medicine (2015)137-141
IF: 0.926
Asian Pacific Journal of Tropical Medicine
journal homepage:www.elsevier.com/locate/apjtm
doi: 1O.1016/S1995-7645(14)60304-7
Effect of combined treatment with cyclophosphamidum and allicin on
neuroblastoma- bearing mice
Xiang-Yang Gao', Xian-Jie Gerig', Wen-Long Zhai2, Xian-Wei Zhang', Yuan Wei\ Guang-
1*JunHou
1Department ofGeneral Surgery, Children's Hospital ofZhengzhou, Zhengzhou, China
2Department ofHepatobiliary Surgery, the First Affiliated Hospital ofZhengzhou University, Zhengzhou, China
ARTICLE INFO
Articlehistory:
Received 15 November 2014
Received in revised form 20December 2014
Accepted 15January 2015
Available online20 February 2015
Keywords:
Allicin
Cyclophosphamide
Neuroblastoma
NB-bearing mice
T cell subsets
ABSTRACT
Objective: To evaluate the efficacy of allicin combined with cyclophosphamide on neuroblastoma
(NB)-bearing mice and explore the immunological mechanism in it. Methods: A total of 30
NB-bearing mice were equally randomized into model group, cyclophosphamide group and
combined therapy group, 10 nudemice were set as normal saline (NS) group. Cyclophosphamide
group and combined therapy group were weekly injected with 60 mg/kg cyclophosphamide
for four weeks; besides, combined therapy group was given with allicin (10 mg/kg/d) by gastric
perlusion for 4 weeks; model group and NSgroup were given with the same volume of NS. Serum
VEGF content was detected by EUSA pre-treating (0 d) and on the 3rd d, 14th d and 28th d; on
29th d, all mice were sacrificed and the tumor, liver, spleen and thymic tissues were weighted.
Tumors were made into paraffin section for detecting tumor cell apoptosis and proliferation by
TUNEL and BrdU method, respectively. Survival curves were drawn by Kaplan-Meier method.
Results: After treatment, both treatment groups relieved on viscera indexes, VEGFlevel, T cell
subsets distribution and tumor growth and each index of combined therapy group was better
than cyclophosphamide group (P<0.05 or 0.01); only combined therapy group could significantly
increase the lifetime of NB-bearing mice (X 2=5.667, P=O.OI7). Conclusions: Allicin can improve
T cell subsets distribution and inhibit VEGF expression through its immunomodulatory activity,
thereby improve the efficiency on NBin coordination with cyclophosphamide.
1. Introduction
Neuroblastoma (NB) is the most common and lethal
extracranial tumor in children. It accounted for 8%-10% of
cancer incidence and 12% of cancer mortality in childrenltl,
The five-year survival rate for children with high risk NB
was only 30%-50%[21. Although the intensive chemotherapy,
radiation, hematopoietic stem cell transplantation
technology had been made considerable progress, the
prognosis of refractory NB was poorlsl, In clinic, variations
of karyotype and cell characteristics, such as tumor
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suppressor genes mutations, chromosome recombination
or deficiency, usually caused tumor to evade treatments of
most drugs or drug resistancelel, Therefore, searching for
novel therapeutic compounds or therapeutic measures that
can work on a wide range of NB cells is desperately needed
for NBtherapylal.
Allicin is the major component and the most biological
compound of pulverized fresh garlicle-el. Allicin has obvious
inhibitory effects on different kinds of tumor cells such
as gastric cancer, colon cancer, liver cancer, and lung
cancer and has been used for clinical therapy as an aid
cancer drug. In the study, we established NB-bearing mice
model and treated them with different schemes to explore
the feasibility and efficacy of combined treatment with
cyclophosphamidum and allicin on NB.
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2. Material and methods
2.1. Experimental animals and cell lines
A total of 50 four-week-old female nudemice (BALB/c-nul
nul weighing 12-14 g were bought from Shanghai Laboratory
Animal Centre of Chinese Academy of Sciences. The animals
were maintained at 25·C with a 12-h lightl12-h dark cycle
in laminar flow cabinets under specific pathogen-free
conditions and given with sterile water and food ad libitum.
The cell line used in experiment was human neuroblastoma
SH-SY5Y cell line bought from Tumor Cell Bank of Chinese
Academy of Medical Sciences.
2.2. Establishment of tumor-bearing mice model and
grouping
When SH-SY5Y cell morphology was well, mice would be
injected. The skin of right forelimbs flank were disinfected,
then cell suspension at 2X107-3X107 cells/mL was injected
(0.1 mL for one mouse). A total of 40 nudemice were injected,
the remaining lO nudemice were injected with 0.1 mL
normal saline (NS) and set as NSgroup.
About 7-9 d after injecting cell suspension (at this time
the tumor volume in mice was about 100 mm), 30 mice
were modeled successfully. They were equally randomized
into three groups: model group, cyclophosphamide group
and combined therapy group. The day of grouping was
regarded as the 1st d of treatment (dl). On the 1st d,
cyclophosphamide group and combined therapy group were
injected with cyclophosphamidum 60 mg/kg through caudal
vein for the first time and on the Sth d for the second time
and so on, a total of four times. Besides, combined therapy
group was given allicin (10 rug/kg/d) by gastric perfusion for
four weeks. Model group and NS group were given the same
volume of NS.
After four-week treatment, on 29th d, all mice were
sacrificed and their tumor, liver, spleen and thymic tissues
were collected for subsequent tests.
2.3. Detection of serum vascular endothelial growth factor
(VEGF)
In order to monitor the curative effect of two treatment
groups, pre-treating (0 d) and on the 3rd d, 14th d, 2Sth d of
the treatment, peripheral blood of each group was collected
through its submandibular vein and centrifuged at 3 000
rpm for 10 min, and the supernatant was reserved. After
collecting all samples, the content of VEGFprotein in serum
was detected by using Mouse VEGFELISA kit.
2.4. Determining ofT lymphocyte subsets in peripheral blood
The detection time points of T lymphocyte subsets in blood
samples were same to those in 2.3. The distribution of T
lymphocyte subsets (Cm+, CD4+, CDS+) was analyzed by flow
cytometry.
2.5. Histology and immunostaining
Formalin-fixed paraffin-embedded sections from model
group and two treatment groups were stained with H&E
or subjected to immnuohistochemistry (IRC) with specific
antibodies. Three hours before sacrifice, mice were
injected with BrdU (1 mU100 g body weight) to evaluate the
proliferation rate of tumor cellslsl, Tumor cells apoptosis
rate was detected by TUNEL method. Apoptotic index (AI)
= apoptosis cell numbers/rapoptosis cell numbers-non-
apoptosis cell numbersjx l Ouss. All immunostains were
evaluated in 10 random microscopic fields selected in viable
tumor regions only (magnificationx200).
2.6. Data processing and analysis
All data was processed by SPSS16.0 software. Data was
presented as mean±standard deviation of at least three
independent experiments. Comparisons were made among
the groups using One-way ANOVA followed by Tukey-
Kramer test or Bonferroni test. Survival curves were drawn
by Kaplan-Meier method and overall comparison and
pairwise comparisons were conducted by Log-Rank method.
A P-value <0.05 was considered significantly different.
3. Results
3.1. Curative effect in each group
After four-week treatment, the tumor weight and visceral
indexes of cyclophosphamide group and combined therapy
group both relieved more significantly than those in model
group (p<0.05 or 0.01), and each index of combined therapy
group was better than cyclophosphamide group (P<0.05 or
0.01), especially the tumor weight and spleen index (P<O.Ol)
(fable 1). Figure 1 showed that compared with model group,
both treatment groups could improve the proportions of
ens', CD4+ T lymphocytes (P<0.05 or 0.01), and combined
therapy group could also significantly reduce the proportion
of CDS+ T lymphocytes (p<0.05). On the 3rd d of treatment,
CD4+/CDS+ ratio in combined therapy group was higher than
that in model group (P<0.05); on the 14th d, CD4+/CDS+ ratio
of cyclophosphamide group began to be higher than that
in model group (p<0.05). Overall, combined therapy could
more timely improve the distribution of T cell subsets than
cyclophosphamide monotherapy.
Before treatment, the serum VEGFcontent of the three NB-
bearing mice groups were similar; after starting treatment,
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Table 1 
Tumor-inhibition rate and visceral indexes in each group.
Groups Tumor weight (g) Tumor-inhibition rate (%) Liver index (mg/g) Spleen index (mg/g) Thymus index (mg/g)
NS group - - 4.78依0.42 7.11依0.33 3.20依1.11
Model group 0.72依0.48 - 7.12依0.93* 1.60依0.22** 1.08依0.26**
Cyclophosphamide group 0.17依0.10## 63.1 6.52依0.71* 2.73依0.98**# 2.10依0.84**##
Combined therapy group 0.05依0.03##▽▽ 92.6 5.10依0.55#▽ 5.49依1.10*##▽▽ 2.95依1.05##▽
Note: * vs. NS group, P<0.05; ** vs. NS group, P<0.01; # vs. Model group, P<0.05; ## vs. Model group, P<0.01; ▽ vs. Cyclophosphamide group, 
P<0.05; ▽▽ vs. Cyclophosphamide group, P<0.01.
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Figure 1. Proportion of T lymphocyte subsets in peripheral blood at different time points. 
Note: * vs. NS group, P<0.05; ** vs. NS group, P<0.01; # vs. Model group, P<0.05; ## vs. Model group, P<0.01.
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VEGF content in both treatment groups decreased rapidly
(P<0.05 or 0.01); once 4-week treatment finished, VEGF
content in combined therapy group and in NS group was
undifferentiated (p>0.05) (Figure 2).
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Figure 2. Serum VEGF content of mice in each group before and
after therapy.
Note: * vs. NS group, P<0.05; ** vs. NS group, P<O.Ol; # vs. Model
group, P<0.05; ## vs. Model group, P<O.Ol.
3.2. Survival analysis ofanimals in each group
Figure 3 showed that the survival curves of mice in
different group compared by Log-Rank method were
statistically significant( X 2=13.387, P=O.OO4). By the end of
treatment, the survival rates of two treatment groups were
higher than model group, and the survival rate of combined
therapy group was also higher than cyclophosphamide
group. Compared with model group, combined therapy
group could significantly prolong the lifetime of tumor-
bearing mice(X 2=5.667, P=0.017),while cyclophosphamide
monotherapy could not reach this effect( X2=1.570, P=0.21O).
3.3. Analysis oftumor cells proliferation and apoptosis
Figure 4 and Figure 5 showed that the tumor cells
proliferation rate in combined therapy group and
cyclophosphamide group both decreased while the apoptosis
rate in both groups increased (p<0.05 or 0.01); proliferation
inhibition effect and apoptosis promoting effect in
combined therapy group were more obvious than those in
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These above results suggested that allicin had obvious
inhibition effect on NB and could increase curative effect
of cyclophosphamidum. In fact, allicin used for fighting
tumor had been reported many times, and the molecular
mechanism of its anti-tumor effect often was attributed to
tumor cells apoptosis induced by allicinlt-l. It had become
clear that the induction of apoptosis was crucial for the anti-
cancer effect of allicin. In yeast system,allicin also caused
a redox-shift in human cell cultures[15] which led to the
execution of tumor cells death which depended on caspases
or was independent of caspases[16,17J.
Tao et al studied the proliferation inhibition effect of
allicin on gastric cancer cell line SGC-7901, they found
allicin could significantly inhibit the proliferation of this
cell line and induce the apoptosis, with its proliferation
inhibition effect on cancer cell in concentration-dependent
mannerl18J. Wang et al applied the combined treatment with
recombined human IL-2 and allicin to treat the pancreatic
tumor-bearing mice, and their results also showed after
the combined therapy the survival time of tumor-bearing
mice was obviously prolonged, the tumor growth was
inhibited, and the serum CD4+ cells, CD8+ cells, NK cells
and IFN- 'Y level had been more significantly improved
than monotherapy group. They thought that this anti-tumor
effect was achieved by activating CD4+ cells, CD8+ cells
and NK cellsltsl. Jiang et a[[20] certified that the combined
therapy of artesunate and allicin could inhibit obviously
the viability of osterosarcoma cells in a concentration and
time dependent manner; and moreover, invasion, motility
and colony formation ability were significantly suppressed
through caspase-3/9 expression and activity enhancement.
Yang RK and his colleagues utilized a mouse model to
investigate the impact of tumor burden on huI4.18-IL-2
treatment efficacy in IV- versus IT-treated animals, and
their results showed that smaller tumor burden at treatment
initiation was associated with increased infiltration of
NK and CD8+ T cells and increased overall survivallztl,
Furthermore, allicin acted on T-cell lymphocytes by
inhibition of the SDFl a -chemokine-induced chemotaxis
and this effect was correlated with an impaired dynamic
of the actin-cytoskeleton[22J. Before treatment, the CD3+
cell level and CD4+/CD8+ ratio in tumor-bearing mice were
lower than normal level, which suggested that the immune
system was compromised and in immunosuppression state.
After treatment (especially the combined treatment), these
indexes were improved significantly which may be caused
by immune modulating activity of allicin[14,23]. Besides,
after treatment, the serum VEGF content of NB-bearing
mice decreased and even equal to the level of mice in NS
group, which maybe caused by allicin directly inhibiting the
expression of VEGF mRNA[24J.
When we design the experiment, the NB-bearing mice
were given allicin (10 mg/kd/d) by gavage to strengthen
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Figure 3. Survival curves of mice in each group.
cyclophosphamide group (p<0.05 or 0.01).
Figure 4. Detennining of tumor cells proliferation rate in three NB-
bearing mice groups by BrdU method.
Figure 5. Comparisons of tumor cells proliferation and apoptosis in
three NB-bearing mice groups.
Allicin is a sulfur compound extracted from garlic
bulbs[lO]. The surveys of epidemiology showed allicin had
inhibition effect on many malignant tumors[ll-13J. In the
study, we combined the treatment with cyclophosphamidum
and allicin on NB-bearing mice for the first time. Our
results displayed that compared with cyclophosphamide
monotherapy, the combined therapy could better inhibit
the tumor growth in NB-bearing mice and improve T
lymphocyte subsets distribution and tumor-bearing mice
lifetime (P<0.05 or 0.01). Besides, we detected VEGF, the
molecular marker of NB, and found after the combined
therapy the serum VEGF content of NB-bearing mice was
same to normal nudemice (p>0.05).
4. Discussion
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the anti-tumor effect of cyclophosphamidum. While in
vivo experiment, it is still unknown thatwhether allicin
strengthened anti-tumor effect of cyclophosphamidum in
a concentration or time dependent manner. Therefore, the
further research needs to confirm the manner of allicin
exerting its anti-tumor effect.
In conclusion, allicin had unique anti-tumor effect on
the treatment of NB and could produce synergetic effect
combining with cyclophosphamide. Allicin exerted its
curative effect through improving T cell subsets distribution
and cellular immunity.
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